Neurotrope’s Bryostatin Improves Cognition in Patients with Advanced Alzheimer’s Disease Based on Further Analysis of Phase 2 Clinical Trial Data

January 5, 2018

Responsive image

NEW YORK, Jan. 5, 2018 /PRNewswire/ — Neurotrope (NASDAQ: NTRP) today announced that a post-hoc analysis of data from its Phase 2 trial in patients with advanced Alzheimer’s disease (AD) found evidence of improvement in cognition in patients receiving the 20μg bryostatin regimen who did…

Category: Precious Metals